SDGR · Insider Trading
Schrodinger, Inc. Common Stock
Every open-market purchase and sale reported by SDGR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | Karen Akinsanya | See Remarks | MIXED | — | −$790.83K |
| 2026-07-17 | Rachit Jain | EVP & CFO | Sell | −875 | −$13.65K |
| 2026-06-29 | Richard Friesner | Director | G | — | — |
| 2026-06-23 | Arun Oberoi | Director | A | +8,141 | — |
| 2026-06-23 | Jeffrey Chodakewitz | Director | A | +8,141 | — |
| 2026-06-23 | Gary L Ginsberg | Director | A | +8,141 | — |
| 2026-06-23 | Nancy Thornberry | Director | A | +8,141 | — |
| 2026-06-23 | Gary Sender | Director | A | +8,141 | — |
| 2026-06-23 | Bridget A van Kralingen | Director | A | +8,141 | — |
| 2026-06-23 | Richard Friesner | Director | A | +8,141 | — |
| 2026-06-23 | Rosana Kapeller-Libermann | Director | A | +8,141 | — |
| 2026-06-23 | Michael Lynton | Director | A | +8,141 | — |
| 2026-04-17 | Rachit Jain | EVP & CFO | Sell | −844 | −$10.76K |
| 2026-04-17 | Ramy Farid | President & CEO | MIXED | +74,527 | −$562.36K |
| 2026-03-06 | Rachit Jain | EVP & CFO | Sell | −1,631 | −$21.03K |
| 2026-03-06 | Ramy Farid | President & CEO | Sell | −3,661 | −$47.25K |
| 2026-03-06 | Jenny Herman | CAO | Sell | −1,383 | −$17.76K |
| 2026-03-06 | Karen Akinsanya | See Remarks | Sell | −1,366 | −$17.63K |
| 2026-03-06 | Robert Lorne Abel | See Remarks | Sell | −1,300 | −$16.65K |
| 2026-03-06 | Kenneth Patrick Lorton | EVP, CTO & COO, Software | Sell | −1,222 | −$15.76K |
| 2026-03-06 | Yvonne Tran | EVP, CLO & CPO | Sell | −1,094 | −$14.11K |
| 2026-03-03 | Kenneth Patrick Lorton | EVP, CTO & COO, Software | A | +37,812 | — |
| 2026-03-03 | Rachit Jain | EVP & CFO | A | +17,130 | — |
| 2026-03-03 | Karen Akinsanya | See Remarks | MIXED | +55,697 | −$26.45K |
| 2026-03-03 | Robert Lorne Abel | See Remarks | A | +37,812 | — |
| 2026-03-03 | Jenny Herman | CAO | A | +9,590 | — |
| 2026-03-03 | Mannix Vartan Aklian | See Remarks | A | +17,130 | — |
| 2026-03-03 | Yvonne Tran | EVP, CLO & CPO | A | +30,918 | — |
| 2026-03-03 | Ramy Farid | President & CEO | MIXED | +112,553 | −$66.15K |
| 2026-03-03 | Richard Friesner | Director | M | +160,527 | +$492.82K |
| 2026-02-12 | Kenneth Patrick Lorton | EVP, CTO & COO, Software | Sell | −925 | −$12.70K |
| 2026-02-12 | Yvonne Tran | EVP, CLO & CPO | Sell | −776 | −$10.71K |
| 2026-02-12 | Jenny Herman | CAO | Sell | −752 | −$10.37K |
| 2026-02-11 | Robert Lorne Abel | See Remarks | Sell | −1,230 | −$16.62K |
| 2025-10-17 | Margaret Dugan | Chief Medical Officer | Sell | −1,395 | −$29.39K |
| 2025-06-20 | Arun Oberoi | Director | A | +5,997 | — |
| 2025-06-20 | Nancy Thornberry | Director | A | +5,997 | — |
| 2025-06-20 | Gary Sender | Director | A | +5,997 | — |
| 2025-06-20 | Michael Lynton | Director | A | +5,997 | — |
| 2025-06-20 | Richard Friesner | Director | A | +5,997 | — |
| 2025-06-20 | Bridget A van Kralingen | Director | A | +1,499 | — |
| 2025-06-20 | Jeffrey Chodakewitz | Director | A | +5,997 | — |
| 2025-06-20 | Rosana Kapeller-Libermann | Director | A | +5,997 | — |
| 2025-06-20 | Gary L Ginsberg | Director | A | +5,997 | — |
| 2025-05-29 | Mannix Vartan Aklian | See Remarks | A | +14,063 | — |
| 2025-05-22 | Rachit Jain | EVP & CFO | A | +9,375 | — |
| 2025-04-15 | Karen Akinsanya | President of R&D, Therapeutics | MIXED | — | −$366.73K |
| 2025-03-10 | Bridget A van Kralingen | Director | A | +10,000 | — |
| 2025-03-07 | Jenny Herman | SVP & Controller | Sell | −666 | −$14.06K |
| 2025-03-04 | Robert Lorne Abel | See Remarks | A | +12,500 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Richard Friesner | Director | 705,917 | $17.29M |
| Ramy Farid | President & CEO | 330,824 | $8.11M |
| Kenneth Patrick Lorton | EVP, CTO & COO, Software | 89,241 | $2.19M |
| Karen Akinsanya | See Remarks | 69,956 | $1.71M |
| Robert Lorne Abel | See Remarks | 55,897 | $1.37M |
| Yvonne Tran | EVP, CLO & CPO | 52,683 | $1.29M |
| Rachit Jain | EVP & CFO | 50,877 | $1.25M |
| Jenny Herman | CAO | 34,804 | $852.70K |
| Mannix Vartan Aklian | See Remarks | 31,193 | $764.23K |
| Gary Sender | Director | 25,388 | $622.01K |
| Jeffrey Chodakewitz | Director | 25,388 | $622.01K |
| Michael Lynton | Director | 25,388 | $622.01K |
| Nancy Thornberry | Director | 25,388 | $622.01K |
| Rosana Kapeller-Libermann | Director | 25,388 | $622.01K |
| Arun Oberoi | Director | 25,388 | $622.01K |
| Gary L Ginsberg | Director | 25,388 | $622.01K |
| Margaret Dugan | Chief Medical Officer | 24,574 | $602.06K |
| Bridget A van Kralingen | Director | 19,640 | $481.18K |
| Geoffrey Craig Porges | EVP & CFO | 18,185 | $445.53K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SDGR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.